Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.
Status:
Completed
Trial end date:
2017-05-15
Target enrollment:
Participant gender:
Summary
This prospective study is intended to evaluate if carvedilol has any potential protective
effect over atorvastatin on the development of contrast-induced nephropathy (CIN) following
cardiac catheterization in patients with moderate to high risk for CIN.